Skip to main content
Federal Circuit· 12/8/2021

Astrazeneca Ab v. Mylan Pharmaceuticals Inc.

Citations

  • 19 F.4th 1325

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • reversing district court’s construction, which applied the standard significant figures rounding convention to the claimed percentage; crediting the specification’s disparagement of deviation within the rounding range and construing the term to apply to a narrower range
  • “[E]ven in the absence of a clear and unmistakable disavowal, . . . the prosecution history can be evaluated to determine how a person of ordinary skill would understand a given claim term.”
  • “[A]ny explanation, elaboration, or qualification pre- sented by the inventor during patent examination is rele- vant, for the role of claim construction is to capture the scope of the actual invention that is disclosed, described, and patented.”

Source: CourtListener parenthetical corpus (CC0).

Read full opinion on CourtListener

Cited by

2 cases in this archive cite this case.

Cites

29 cases in this archive are cited by this case; the 20 most cited are listed.

Other cases named Astrazeneca Ab v. Mylan Pharmaceuticals Inc.

2 other CourtListener records share this case name.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.